Loading clinical trials...

RECRUITINGPHASE1/PHASE2

A Study of BMS-986482 Alone or as Combination Therapy in Participants With Advanced Solid Tumors

A Phase 1/2 Study of BMS-986482 as Monotherapy or Combination Therapy in Participants With Advanced Solid Tumors

NCT06697197•Bristol-Myers Squibb

Summary

The purpose of this study is to test the safety and efficacy of BMS-986482 alone and as combination therapy in participants with advanced solid tumors.

Eligibility

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•All participants must have a histologically or cytologically confirmed, advanced, unresectable/metastatic, solid malignancy measurable by RECIST v1.1, and have received, be refractory to, ineligible for, intolerant of, or refused existing therapy(ies) known to provide clinical benefit for the condition of the participant.
•Participant must be ≥ 18 years or the legal age of consent in the jurisdiction in which the study is taking place, inclusive, at the time of signing the ICF.

Exclusion Criteria

•History of life threatening immune mediated toxicity related to prior T-cell agonist or checkpoint inhibitor therapy, except those that are unlikely to re-occur with standard countermeasures.
•Any significant acute or chronic medical illness which would interfere with study intervention or follow-up in the opinion of the investigator.

Locations (21)

University of California, Irvine (UCI) Health - UC Irvine Medical Center

Irvine, California, United States

The Angeles Clinic and Research Institute - West Los Angeles Office

Los Angeles, California, United States

Local Institution - 0008

Aurora, Colorado, United States

John Theurer Cancer Center at Hackensack University Medical Center

Hackensack, New Jersey, United States

Northwell Health/ RJ Zuckerberg Cancer Center

Lake Success, New York, United States

Levine Cancer Institute

Charlotte, North Carolina, United States

Fred Hutchinson Cancer Center

Seattle, Washington, United States

UZ Gent

Ghent, Oost-Vlaanderen, Belgium

Rigshospitalet

Copenhagen, Capital Region, Denmark

Assistance Publique Hôpitaux de Marseille - Hôpital de la Timone

Marseille, Bouches-du-Rhône, France

Key Dates

Start Date

February 17, 2025

Primary Completion Date

January 4, 2029

Completion Date

January 5, 2029

Last Updated

February 3, 2026

Enrollment

413

ESTIMATED participants

Conditions

Advanced Solid Tumors

Interventions

BMS-986482

DRUG

Nivolumab and rHuPH20

DRUG

Nivolumab/relatlimab/rHuPH20

DRUG

Bevacizumab

DRUG

Contacts

BMS Clinical Trials Contact Center www.BMSClinicalTrials.com

CONTACT

855-907-3286 Clinical.Trials@bms.com

First line of the email MUST contain NCT # and Site #.

CONTACT

A Study to Assess the Safety, Tolerability, and Efficacy of NDI-219216 in Patients With Advanced Solid Tumors.

NCT06898450

Advanced Solid Tumors CancerMSI-H Cancer

View study

RECRUITINGPHASE1

A Study of ASP1002 in Adults for Treatment of Solid Tumors

NCT05719558

Advanced Solid Tumors

View study

RECRUITINGPHASE1

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: February 3, 2026Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

A Study of BMS-986482 Alone or as Combination Therapy in Participants With Advanced Solid Tumors

Inclusion Criteria

Exclusion Criteria

A Study to Assess the Safety, Tolerability, and Efficacy of NDI-219216 in Patients With Advanced Solid Tumors.

A Study of ASP1002 in Adults for Treatment of Solid Tumors

A Study With NKT5097 for Adults With Advanced/Metastatic Solid Tumors

A Phase I/II Study of Sacituzumab Govitecan Plus Berzosertib in Small Cell Lung Cancer, Extra-Pulmonary Small Cell Neuroendocrine Cancer and Homologous Recombination-Deficient Cancers Resistant to PARP Inhibitors

Study of DT-7012 as a Single Agent and in Combination With an Immune Checkpoint Inhibitor in Participants With Advanced Solid Tumors

A Study to Learn More About How Well Treatment With Sevabertinib (BAY 2927088) Tablets Works and How Safe it is in Participants Who Have a Solid Tumor With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)